Edgewise Therapeutics, Inc. (EWTX)

NASDAQ: EWTX · IEX Real-Time Price · USD
8.86
+0.28 (3.26%)
At close: Dec 2, 2022 4:00 PM
9.13
+0.27 (3.05%)
After-hours: Dec 2, 2022 4:24 PM EST
3.26%
Market Cap 542.37M
Revenue (ttm) n/a
Net Income (ttm) -60.92M
Shares Out 51.84M
EPS (ttm) 2.89
PE Ratio 3.07
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 205,267
Open 8.51
Previous Close 8.58
Day's Range 8.3 - 8.91
52-Week Range 5.41 - 22.41
Beta n/a
Analysts Buy
Price Target 24.28 (+174.0%)
Earnings Date Nov 9, 2022

About EWTX

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise T... [Read more]

Industry Biotechnology
IPO Date Mar 26, 2021
Employees 50
Stock Exchange NASDAQ
Ticker Symbol EWTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for EWTX stock is "Buy." The 12-month stock price forecast is 24.28, which is an increase of 174.04% from the latest price.

Price Target
$24.28
(174.04% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Wall Street Analysts Believe Edgewise Therapeutics, Inc. (EWTX) Could Rally 133%: Here's is How to Trade

The mean of analysts' price targets for Edgewise Therapeutics, Inc. (EWTX) points to a 133.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agree...

2 weeks ago - Zacks Investment Research

Edgewise Therapeutics, Inc. (EWTX) Upgraded to Buy: Here's What You Should Know

Edgewise Therapeutics, Inc. (EWTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 month ago - Zacks Investment Research

Wall Street Analysts Believe Edgewise Therapeutics, Inc. (EWTX) Could Rally 157%: Here's is How to Trade

The consensus price target hints at a 156.9% upside potential for Edgewise Therapeutics, Inc. (EWTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in...

1 month ago - Zacks Investment Research

Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 27th Intern...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treat...

1 month ago - Business Wire

Purple Innovation and Edgewise Therapeutics See Activist Investor Action

These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities.

Other symbols: PRPL
2 months ago - Market Watch

Edgewise Therapeutics Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underw...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc. (NASDAQ: EWTX) today announced the closing of its upsized underwritten public offering of 13,372,093 shares of its common stock at a price to...

2 months ago - Business Wire

Edgewise Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc. (NASDAQ: EWTX) today announced the pricing of its upsized underwritten public offering of 11,627,907 shares of its common stock at a price to...

2 months ago - Business Wire

Edgewise (EWTX) Up 9.37% on Positive Data From BMD Study

Edgewise (EWTX) stock gains on upbeat interim results from the ARCH study of its lead candidate EDG-5506 in adults with Becker Muscular Dystrophy (BMD).

2 months ago - Zacks Investment Research

Edgewise Therapeutics Announces Proposed Offering of Common Stock

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering of $100 milli...

2 months ago - Business Wire

Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treat...

2 months ago - Business Wire

Edgewise Therapeutics Announces FDA Authorization for Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenn...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treat...

2 months ago - Business Wire

Edgewise Therapeutics Reports Second Quarter 2022 Financial Results

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treat...

4 months ago - Business Wire

Edgewise Therapeutics to Present at the Wedbush PacGrow Healthcare Conference on August 9

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treat...

4 months ago - Business Wire

6 Blue-Chip Stocks to Sell Now

This article is about 6 blue-chip stocks to sell now. The stocks are overvalued or could fall due to the recession or from a downgrade in analysts' forecasts of their earnings.

Other symbols: ACBAFMDAGSCURIGEVO
4 months ago - InvestorPlace

Edgewise Therapeutics Now Enrolling CANYON Phase 2 Clinical Trial of EDG-5506 in Individuals with Becker Muscular Dys...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treat...

4 months ago - Business Wire

RBC Capital Says This Dystrophy Stock 'Is Worth A Look'

RBC Capital says Edgewise Therapeutics Inc's (NASDAQ: EWTX) interim results from the ARCH study of EDG-5506 in Becker Muscular Dystrophy (BMD) improve reward/risk into October functional readout at 15 m...

5 months ago - Benzinga

Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treat...

5 months ago - Business Wire

New 2-Month Interim Data from the ARCH Open Label Study of EDG-5506 in Individuals with Becker Muscular Dystrophy (BM...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare musc...

5 months ago - Business Wire

Edgewise Therapeutics Reports First Quarter 2022 Financial Results

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treat...

6 months ago - Business Wire

Edgewise-Funded Natural History Trial of Becker Muscular Dystrophy (BMD) Now Enrolling

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatm...

7 months ago - Business Wire

Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2022 Annual...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treat...

8 months ago - Business Wire